Sunpharma share price

Sunpharma share price

It is a private sector pharmaceuticals company. Sun Pharmaceuticals Industries is among the top 10 consumer healthcare companies in India, Romania, Nigeria and Myanmar

Sun Pharmaceuticals Industries manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. Headquartered in Mumbai,

Sun Pharmaceuticals Industries registered a revenue of Rs 7,806.70 crore in FY17. Sun Pharmaceuticals Industries is the world's fourth largest specialty generic pharmaceuticals company and a provider of medicines in over 150 countries.. Its key focus markets comprise India, Russia, Romania, Nigeria, South Africa and Myanmar. Sun Pharma's R&D unit comprises about 2,000 scientists and investments of approximately 8 per cent of annual revenues. Sun Pharma's global presence is supported by 41 manufacturing facilities spread across six continents, R&D centres across the globe and a workforce of more than 30,000 comprising over 50 nationalities. As of September 2017, Sun Pharma promoters held a 54.38 per cent stake in the company, while the remaining 45.62 per cent was with the public.

Sun Pharma shares

Sun Pharmaceuticals Industries shares trade with symbol SUNPHARMA on stock exchanges BSE and NSE.

Sun Pharmaceuticals Industries' key focus areas include CNS, dermatology, cardiology, oncology and ophthalmics. The pharma company has a comprehensive basket of 584 ANDAs, 41 NDAs and 1 BLA filed and 427 ANDAs and 36 NDAs approved across multiple therapies. In FY17, its key contributors to revenues included Imatinib Mesylate Tablets.

History

Sun Pharmaceutical Industries was founded in 1983 with a manufacturing plant in Vapi, Gujarat. Sun Pharma has grown to become India's largest and most valuable pharmaceutical company by market capitalisation with global revenues of over $4.5 billion.

Background

Sun Pharmaceuticals Industries completed the merger with Ranbaxy in 2015 - its largest acquisition. In April 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth $4-billion that included a debt of $800 million.

Registered office

SPARC, Tandalja, Vadodara, Gujarat-390020

Source-By-NDTv 

key words-Sunpharma share price,Sun pharma share price,Sunpharma shares,Sunpharma NSE